Literature DB >> 33658371

Monocyte markers correlate with immune and neuronal brain changes in REM sleep behavior disorder.

Kristine Farmen1, Sara K Nissen1, Morten G Stokholm2, Alex Iranzo3,4, Karen Østergaard5, Mónica Serradell3, Marit Otto6, Kristina B Svendsen5, Alicia Garrido4,7, Dolores Vilas4,7, Per Borghammer2, Joan Santamaria3, Arne Møller2, Carles Gaig3,4, David J Brooks2,8, Eduardo Tolosa4,7, Nicola Pavese2,8, Marina Romero-Ramos9.   

Abstract

Synucleinopathies are neurodegenerative diseases with both central and peripheral immune responses. However, whether the peripheral immune changes occur early in disease and their relation to brain events is yet unclear. Isolated rapid-eye-movement (REM) sleep behavior disorder (iRBD) can precede synucleinopathy-related parkinsonism and provides a prodromal phenotype to study early Parkinson's disease events. In this prospective case-control study, we describe monocytic markers in a cohort of iRBD patients that were associated with the brain-imaging markers of inflammation and neuronal dysfunction. Using 11C-PK11195 positron emission tomography (PET), we previously showed increased immune activation in the substantia nigra of iRBD patients, while 18F-DOPA PET detected reduced putaminal dopaminergic function. Here we describe that patients' blood monocytic cells showed increased expression of CD11b, while HLA-DR expression was decreased compared to healthy controls. The iRBD patients had increased classical monocytes and mature natural killer cells. Remarkably, the levels of expression of Toll-like receptor 4 (TLR4) on blood monocytes in iRBD patients were positively correlated with nigral immune activation measured by 11C-PK11195 PET and negatively correlated with putaminal 18F-DOPA uptake; the opposite was seen for the percentage of CD163+ myeloid cells. This suggesting a deleterious role for TLR4 and, conversely, a protective one for the CD163 expression. We show an association between peripheral blood monocytes and brain immune and dopaminergic changes in a synucleinopathy-related disorder, thus suggesting a cross-talk among periphery and brain during the disease.

Entities:  

Keywords:  CD163; TLR4; monocytes; neuroinflammation; positron emission tomography

Year:  2021        PMID: 33658371     DOI: 10.1073/pnas.2020858118

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  7 in total

Review 1.  Neuroinflammation and Immune Changes in Prodromal Parkinson's Disease and Other Synucleinopathies.

Authors:  Miriam Højholt Terkelsen; Ida H Klaestrup; Victor Hvingelby; Johanne Lauritsen; Nicola Pavese; Marina Romero-Ramos
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 2.  New Insights and Implications of Natural Killer Cells in Parkinson's Disease.

Authors:  Kelly B Menees; Jae-Kyung Lee
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

3.  Circulating Soluble CD163: A Potential Predictor for the Functional Outcome of Acute Ischemic Stroke.

Authors:  Houchao Sun; Xiaogang Zhang; Jingxi Ma; Zhao Liu; Yunwen Qi; Li Fang; Yongling Zheng; Zhiyou Cai
Journal:  Front Neurol       Date:  2021-12-14       Impact factor: 4.003

4.  Peripheral Immune Cell Numbers and C-Reactive Protein in Parkinson's Disease: Results from a Population-Based Study.

Authors:  Lisanne J Dommershuijsen; Rikje Ruiter; Nicole S Erler; Dimitris Rizopoulos; M Arfan Ikram; M Kamran Ikram
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.568

5.  Brain microglia activation and peripheral adaptive immunity in Parkinson's disease: a multimodal PET study.

Authors:  Shu-Ying Liu; Hong-Wen Qiao; Tian-Bin Song; Xiu-Lin Liu; Yun-Xia Yao; Chun-Song Zhao; Olivier Barret; Sheng-Li Xu; Yan-Ning Cai; Gilles D Tamagnan; Vesna Sossi; Jie Lu; Piu Chan
Journal:  J Neuroinflammation       Date:  2022-08-29       Impact factor: 9.587

6.  Association of Parasomnia Symptoms with Risk of Childhood Asthma and the Role of Preterm Birth.

Authors:  Yiting Chen; Anda Zhao; Jiajun Lyu; Yabin Hu; Yong Yin; Jiajie Qu; Shilu Tong; Shenghui Li
Journal:  Nat Sci Sleep       Date:  2022-09-03

Review 7.  Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson's Disease.

Authors:  Johan Wallin; Per Svenningsson
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.